Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200433, China.
BMC Cancer. 2023 Oct 23;23(1):1017. doi: 10.1186/s12885-023-11485-y.
The use of Anti-PD-1 therapy has yielded promising outcomes in hepatocellular carcinoma (HCC). However, limited research has been conducted on the overall survival (OS) of patients with varying tumor responses and treatment duration.
This retrospective study analyzed HCC patients who received sintilimab between January 2019 and December 2020 at four centers in China. The evaluation of tumor progression was based on Response Evaluation Criteria in Solid Tumors version 1.1. The study investigated the correlation between tumor response and OS, and the impact of drug use on OS following progressive disease (PD).
Out of 441 treated patients, 159 patients satisfied the inclusion criteria. Among them, 77 patients with disease control exhibited a significantly longer OS compared to the 82 patients with PD (median OS 26.0 vs. 11.3 months, P < 0.001). Additionally, the OS of patients with objective response (OR) was better than that of patients with stable disease (P = 0.002). Among the 47 patients with PD who continued taking sintilimab, the OS was better than the 35 patients who discontinued treatment (median OS 11.4 vs. 6.9 months, P = 0.042).
In conclusion, the tumor response in HCC patients who received sintilimab affects OS, and patients with PD may benefit from continued use of sintilimab.
抗 PD-1 疗法在肝细胞癌（HCC）中已取得了令人瞩目的疗效。然而，对于肿瘤反应和治疗持续时间不同的患者的总生存期（OS），相关研究仍较少。
本回顾性研究分析了 2019 年 1 月至 2020 年 12 月在中国四家中心接受信迪利单抗治疗的 HCC 患者。肿瘤进展的评估基于实体瘤反应评价标准 1.1 版。研究调查了肿瘤反应与 OS 的相关性，以及疾病进展（PD）后药物使用对 OS 的影响。
在 441 例接受治疗的患者中，159 例符合纳入标准。其中，77 例疾病控制患者的 OS 明显长于 82 例 PD 患者（中位 OS 26.0 与 11.3 个月，P<0.001）。此外，客观缓解（OR）患者的 OS 优于疾病稳定（SD）患者（P=0.002）。在 47 例 PD 继续接受信迪利单抗治疗的患者中，OS 优于 35 例停止治疗的患者（中位 OS 11.4 与 6.9 个月，P=0.042）。
总之，接受信迪利单抗治疗的 HCC 患者的肿瘤反应影响 OS，PD 患者可能受益于继续使用信迪利单抗。
